Functional and molecular analyses reveal impaired HSPCs in Multiple Myeloma patients post-induction
Stem Cells Translational Medicine · 2025
DOI: 10.1093/stcltm/szaf061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, 2025. Verfasst von Thanh Mai Baumhardt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, University Hospital of Ulm, 89081 Ulm, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ulm University.
Abstract (Originalsprache)
High-dose chemotherapy and consecutive autologous stem cell transplantation (ASCT) remain the backbone of treatment for transplant-eligible patients of Multiple Myeloma (MM). However, patients are still at high risk of relapse or treatment-related complications. Hence, by understanding the function of hematopoietic stem and progenitor cells (HSPCs) from MM patients in more detail, transplant outcomes in MM patients might be further improved. We combine in our study functional analyses of the potential of HSPCs from newly diagnosed (NDMM) and chemotherapy treated MM patients in a xenotransplant model system with in depth single cells sequencing analysis to provide novel data that might inform clinical routine to improve the outcome of ASCT in MM. Our data demonstrate that (i) HSPCs from treated MM patients are indeed significantly impaired in their overall reconstitution potential and provide a reduced level of B-cells in comparison to HSPCs from age-matched healthy donors and NDMM patients. (ii) We further demonstrate that CD34+ HSPCs acquire a high-risk MM expression profile signature upon induction treatment, which likely adds to the risk of relapse. This high-risk MM expression profile signature relies within CD34+ HSPCs primarily in granulocyte/macrophage progenitors (GMPs), megakaryocyte Erythroid Progenitors (MEPs) and monocytes, while hematopoietic stem cells (HSCs) stay unaffected by transcriptional changes. These data suggest that the elimination of myeloid progenitors and more mature monocytes (likely by purification for HSCs) in HSPCs harvests from treated MM patients for subsequent ASCT might improve transplant outcomes by avoiding re-infusion of cells with a dysregulated and disease-linked transcriptional program.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine III, University Hospital of Ulm, 89081 Ulm, Germany.
- Institute of Molecular Medicine, Ulm University, 89081 Ulm, Germany.
- Department of Cardiothoracic and Vascular Surgery, University Hospital of Ulm, 89081 Ulm, Germany.
- Charité University Hospital, 12203 Berlin, Germany.
- Division of Chromatin Networks, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Aging research Center (Arc), Ulm University, 89081 Ulm, Germany.
ORCID-Profile: Thanh Mai Baumhardt, Markus Hoenicka, Andreas Liebold
Förderung
- Ulm University
Zitieren
APA
Baumhardt, T. M., Amoah, A., Hoenicka, M., Liebold, A., Sakk, V., Soller, K., Vollmer, A., Kull, M., Kronke, J., Mallm, J. P., Geiger, H., & Mulaw, M. (2025). Functional and molecular analyses reveal impaired HSPCs in Multiple Myeloma patients post-induction. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szaf061
Vancouver
Baumhardt TM, Amoah A, Hoenicka M, Liebold A, Sakk V, Soller K, et al. Functional and molecular analyses reveal impaired HSPCs in Multiple Myeloma patients post-induction. Stem Cells Translational Medicine. 2025. doi:10.1093/stcltm/szaf061
BibTeX
@article{Baumhardt2025,
author = {Baumhardt, Thanh Mai and Amoah, Amanda and Hoenicka, Markus and Liebold, Andreas and Sakk, Vadim and Soller, Karin and Vollmer, Angelika and Kull, Miriam and Kronke, Jan and Mallm, Jan-Philipp and Geiger, Hartmut and Mulaw, Medhanie},
title = {Functional and molecular analyses reveal impaired HSPCs in Multiple Myeloma patients post-induction},
journal = {Stem Cells Translational Medicine},
year = {2025},
doi = {10.1093/stcltm/szaf061}
}
EUVIMED